Growing Focus on Stem Cell Research Is Expected to Boost the Global Cell Culture Protein Surface Coating Market Through 2019
The Global Cell Culture Protein Surface Coating Market is expected to post a CAGR of 12.91% from 2014 to 2019, thanks to a growing focus on stem cell research, according to a new report from research firm TechNavio.
Stem cell therapy plays a vital role in the treatment of several serious diseases including neurodegenerative diseases, cardiac diseases and diabetes. Presently, it is most commonly used for bone marrow transplants.
Cell culture protein surface coating products help researchers improve the adhesion, proliferation and growth of cells being cultured for these treatments.
“The high potential of stem cells in the treatment of severe diseases has resulted in demand for advanced cell culture products for stem cell production and study,” says Faisal Ghaus, Vice President of TechNavio.
The latest report by TechNavio draws attention to animal-free synthetic protein surface coatings that have a broad range of applications in several areas, including biopharmaceutical production and other research. There has been a huge demand for these coatings from the pharmaceutical and biotechnology industries, as they reduces the risk of contamination.
“Many vendors like BD are focusing on the development of animal-free synthetic protein surface coating products so as to meet increasing industry demand,” says Ghaus.
Key Information Covered in the Report:
• Market segmentation, size and forecast through 2019
• Market Growth Drivers:
• Growing Focus on Stem Cell Research
• For a full detailed list, view the report.
• Market Challenges:
• Disadvantages of Animal-derived Protein Surface Coatings
• For a full detailed list, view the report.
• Market Trends:
• Animal-free Synthetic Protein Surface Coating
• For a full detailed list, view the report.
Key Questions Answered in this Report:
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
• Key Vendors:
• Becton, Dickinson and Co. (BD)
• Corning Inc.
• EMD Millipore Corp.
• Sigma-Aldrich Corp.
• Other Prominent Vendors:
• Abcam
• BioMedTech Laboratories
• Cedarlane Laboratories
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance